{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:16:47Z","timestamp":1780499807000,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":1655,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1038\/s41379-018-0034-6","type":"journal-article","created":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T18:30:42Z","timestamp":1518633042000},"page":"1155-1163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["PD-L1 expression in inflammatory myofibroblastic tumors"],"prefix":"10.1016","volume":"31","author":[{"given":"Tricia R","family":"Cottrell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh T","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D","family":"Gocke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Ogurtsova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janis M","family":"Taube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A","family":"Belchis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-018-0034-6_bib1","unstructured":"Coffin CM, Fletcher JA. Inflammatory myofibroblastic tumor. In: Fletcher CDM, World Health Organization, International Agency for Research on Cancer, editors. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press; 2013."},{"key":"10.1038\/s41379-018-0034-6_bib2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/01.pas.0000213393.57322.c7","article-title":"Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases","volume":"31","author":"Coffin","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41379-018-0034-6_bib3","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1158\/2159-8290.CD-14-0377","article-title":"Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions","volume":"4","author":"Lovly","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1038\/s41379-018-0034-6_bib4","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/PAS.0000000000000404","article-title":"Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement","volume":"39","author":"Antonescu","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41379-018-0034-6_bib5","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/PAS.0000000000000677","article-title":"ETV6-NTRK3 is expressed in a subset of ALK-negative inflammatory myofibroblastic tumors","volume":"40","author":"Alassiri","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41379-018-0034-6_bib6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/his.12910","article-title":"ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours","volume":"69","author":"Yamamoto","year":"2016","journal-title":"Histopathology"},{"key":"10.1038\/s41379-018-0034-6_bib7","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1056\/NEJMoa1007056","article-title":"Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor","volume":"363","author":"Butrynski","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-018-0034-6_bib8","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1038\/s41379-018-0034-6_bib9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","article-title":"PD-1\/PD-L1 inhibitors","volume":"23","author":"Sunshine","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"10.1038\/s41379-018-0034-6_bib10","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jamaoncol.2017.0115","article-title":"Association of HIV status with local immune response to anal squamous cell carcinoma: implications for immunotherapy","volume":"3","author":"Yanik","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1038\/s41379-018-0034-6_bib11","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1038\/s41379-018-0034-6_bib12","doi-asserted-by":"crossref","first-page":"e1094598","DOI":"10.1080\/2162402X.2015.1094598","article-title":"Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: implication for optional anti-PD-1\/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients","volume":"5","author":"Hong","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1038\/s41379-018-0034-6_bib13","doi-asserted-by":"crossref","first-page":"e1108514","DOI":"10.1080\/2162402X.2015.1108514","article-title":"EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1alpha and STAT3","volume":"5","author":"Koh","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1038\/s41379-018-0034-6_bib14","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.jtho.2016.12.026","article-title":"Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 >\/=50% expression in lung adenocarcinoma","volume":"12","author":"Rangachari","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1038\/s41379-018-0034-6_bib15","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1038\/s41379-018-0034-6_bib16","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1053\/j.semdp.2016.08.007","article-title":"Inflammatory myofibroblastic tumour","volume":"33","author":"McDermott","year":"2016","journal-title":"Semin Diagn Pathol"},{"key":"10.1038\/s41379-018-0034-6_bib17","doi-asserted-by":"crossref","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1038\/s41379-018-0034-6_bib18","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/01676830.2017.1279645","article-title":"Spontaneous regression of inflammatory myofibroblastic tumor of the orbit: a case report and review of literature","volume":"36","author":"Habib","year":"2017","journal-title":"Orbit"},{"key":"10.1038\/s41379-018-0034-6_bib19","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/path.4836","article-title":"ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma","volume":"241","author":"Lee","year":"2017","journal-title":"J Pathol"},{"key":"10.1038\/s41379-018-0034-6_bib20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/PAS.0b013e318200cfd5","article-title":"Epithelioid inflammatory myofibroblastic sarcoma: an aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK","volume":"35","author":"Marino-Enriquez","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41379-018-0034-6_bib21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.humpath.2014.11.001","article-title":"Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment","volume":"46","author":"D'Angelo","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1038\/s41379-018-0034-6_bib22","doi-asserted-by":"crossref","unstructured":"Toulmonde M, Adam J, Bessede A, et al. Integrative assessment of expression and prognostic value of PDL1, IDO, and kynurenine in 371 primary soft tissue sarcomas with genomic complexity. J Clin Oncol. 2016;34:15_suppl,\u00a011008-11008.","DOI":"10.1200\/JCO.2016.34.15_suppl.11008"},{"key":"10.1038\/s41379-018-0034-6_bib23","doi-asserted-by":"crossref","first-page":"e1278100","DOI":"10.1080\/2162402X.2016.1278100","article-title":"PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas","volume":"6","author":"Bertucci","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1038\/s41379-018-0034-6_bib24","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-016-2451-6","article-title":"Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma","volume":"16","author":"Kim","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1038\/s41379-018-0034-6_bib25","doi-asserted-by":"crossref","first-page":"e82870","DOI":"10.1371\/journal.pone.0082870","article-title":"Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas","volume":"8","author":"Kim","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1038\/s41379-018-0034-6_bib26","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1038\/s41379-018-0034-6_bib27","doi-asserted-by":"crossref","unstructured":"Toulmonde M, Penel N, Adam J, et al. Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial. JAMA Oncol. 2017. https:\/\/doi.org\/10.1001\/jamaoncol.2017.1617.","DOI":"10.1001\/jamaoncol.2017.1617"},{"key":"10.1038\/s41379-018-0034-6_bib28","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1158\/1078-0432.CCR-16-2375","article-title":"Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer","volume":"23","author":"Ratcliffe","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1038\/s41379-018-0034-6_bib29","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1038\/s41379-018-0034-6_bib30","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2017.0013","article-title":"A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer","volume":"3","author":"Rimm","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1038\/s41379-018-0034-6_bib31","doi-asserted-by":"crossref","unstructured":"Gaule P, Smithy JW, Toki M, et al. A quantitative comparison of antibodies to programmed cell death 1 ligand 1. JAMA Oncol. 2017;3:256\u20139.","DOI":"10.1001\/jamaoncol.2016.3015"},{"key":"10.1038\/s41379-018-0034-6_bib32","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1158\/1078-0432.CCR-16-1821","article-title":"PD-L1 expression in melanoma: a quantitative immunohistochemical antibody comparison","volume":"23","author":"Sunshine","year":"2017","journal-title":"Clin Cancer Res"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41379-018-0034-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-018-0034-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222016994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222016994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-018-0034-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:52:31Z","timestamp":1760230351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222016994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0893395222016994"],"URL":"https:\/\/doi.org\/10.1038\/s41379-018-0034-6","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-L1 expression in inflammatory myofibroblastic tumors","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-018-0034-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}